Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...
FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...
Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for ...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular ...
Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.
JPMorgan's Morgan Health co-led an $80 million investment in Cortica, an autism care provider, marking its seventh investment ...
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...
Biohaven's Phase 3 trial of taldefgrobep alfa failed to meet its primary endpoint in spinal muscular atrophy, causing a 10% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback